Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

FRBRX Franklin Biotechnology Discovery R6

  • Fund
  • FRBRX
  • Price as of: Dec 11, 2017
  • $154.45
  • + $0.27
  • + 0.18%
  • Category
  • Health & Biotech Equities

FRBRX - Profile

Vitals

  • YTD Return 16.3%
  • 3 Yr Annualized Return 1.0%
  • 5 Yr Annualized Return 18.1%
  • Net Assets $1.4 B
  • Holdings in Top 10 52.4%

52 WEEK LOW AND HIGH

$154.45
$132.84
$169.98

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.63%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 34.12%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000,000

IRA

N/A

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 16.3%
  • 3 Yr Annualized Total Return 1.0%
  • 5 Yr Annualized Total Return 18.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.17%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Franklin Biotechnology Discovery Fund
  • Fund Family Name Franklin Templeton Investments
  • Inception Date May 01, 2013
  • Shares Outstanding N/A
  • Share Class Retirement
  • Currency USD
  • Domiciled Country United States
  • Manager Evan S. McCulloch

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 16.3% -14.9% 40.8% 66.07% 4
1 Yr 11.4% -14.8% 55.1% 90.09% 5
3 Yr 1.0% * -7.5% 17.2% 94.44% 5
5 Yr 18.1% * 9.3% 22.3% 42.72% 3
10 Yr 13.5% * 6.1% 17.4% 18.45% 1

* Annualized


Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -20.6% -29.8% 2.6% 79.09% 5
2015 -2.4% -20.4% 14.5% 52.73% 3
2014 29.3% -5.8% 33.7% 6.36% 1
2013 N/A -2.6% 65.2% N/A N/A
2012 N/A -5.3% 36.5% N/A N/A

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 16.3% -14.9% 40.8% 66.67% 4
1 Yr 11.4% -18.3% 52.9% 84.55% 5
3 Yr 1.0% * -14.2% 16.4% 88.89% 5
5 Yr 18.1% * 9.1% 22.3% 40.78% 2
10 Yr 13.5% * 6.1% 17.4% 16.50% 1

* Annualized


Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -20.6% -25.1% 6.3% 81.65% 5
2015 6.1% -16.6% 39.1% 66.06% 4
2014 40.6% -5.8% 100.0% 20.18% 1
2013 N/A -5.1% 398.7% N/A N/A
2012 N/A -2.6% 475.8% N/A N/A

NAV & Total Return History

FRBRX - Holdings

Filings data as of: Sep 30, 2017

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Net Assets 1.4 B 18.6 M 47 B 16.96% 3
Number of Holdings 102 31 356 10.71% 2
Net Assets in Top 10 798 M 11 M 20.2 B 13.39% 2
Weighting of Top 10 52.4% 20.0% 74.0% 6.25% 1

Top 10 Holdings

  1. Celgene Corp 10.02%
  2. Gilead Sciences Inc 4.54%
  3. Biogen Inc 4.86%
  4. Regeneron Pharmaceuticals Inc 4.67%
  5. Incyte Corp 5.01%
  6. Vertex Pharmaceuticals Inc 4.00%
  7. Alexion Pharmaceuticals Inc 8.02%
  8. Illumina Inc 4.19%
  9. Clovis Oncology Inc 3.48%
  10. Neurocrine Biosciences Inc 3.61%

Asset Allocation

Weighting Category Low Category High FRBRX % Rank Quintile
Stocks
97.38% 92.56% 99.95% 16.96% 3
Cash
2.19% 0.00% 6.94% 12.50% 2
Other
0.43% 0.00% 3.82% 7.14% 2
Preferred Stocks
0.00% 0.00% 2.89% 13.39% 5
Convertible Bonds
0.00% 0.00% 0.46% 3.57% 4
Bonds
0.00% 0.00% 4.69% 6.25% 4

Stock Sector Breakdown

Weighting Category Low Category High FRBRX % Rank Quintile
Healthcare
97.30% 11.15% 99.58% 6.25% 1
Energy
0.09% 0.00% 0.09% 0.89% 1
Utilities
0.00% 0.00% 0.95% 1.79% 4
Technology
0.00% 0.00% 65.49% 26.79% 5
Real Estate
0.00% 0.00% 1.52% 1.79% 4
Industrials
0.00% 0.00% 8.26% 6.25% 4
Financial Services
0.00% 0.00% 2.90% 4.46% 4
Communication Services
0.00% 0.00% 0.00% 0.89% 4
Consumer Defense
0.00% 0.00% 1.65% 11.61% 4
Consumer Cyclical
0.00% 0.00% 7.41% 8.04% 4
Basic Materials
0.00% 0.00% 2.52% 6.25% 4

Stock Geographic Breakdown

Weighting Category Low Category High FRBRX % Rank Quintile
US
94.96% 59.21% 99.70% 5.36% 1
Non US
2.42% 0.00% 38.71% 29.46% 5

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.63% 0.10% 4.31% 63.39% 1
Management Fee 0.59% 0.09% 1.25% 13.39% 1
12b-1 Fee N/A 0.00% 1.00% N/A N/A
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Turnover 34.12% 0.00% 699.00% 17.86% 3

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Net Income Ratio -0.17% -2.22% 1.46% 30.36% 2

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

FRBRX - Managers

Evan S. McCulloch

Lead Manager

Start Date

Sep 15, 1997

Tenure

20.22

Tenure Rank

0.5%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.


Steven Kornfeld

Manager

Start Date

Sep 15, 2015

Tenure

2.21

Tenure Rank

20.9%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.


Tenure Analysis

Category Low

0.3

Category High

20.1

Category Average

9.08

Category Mode

0.7